Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleNeural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Author(s)Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE.
Journal, Volume, IssueJ Psychopharmacol. 2011 Jan;25(1):121-30.
Major outcome(s)CBD reduces anxiety in patients with generalized social anxiety disorder.
IndicationAnxietyAbstract
MedicationCannabidiol

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the present study was to investigate this in patients with generalized social anxiety disorder (SAD) using functional neuroimaging. Regional cerebral blood flow (rCBF) at rest was measured twice using (99m)Tc-ECD SPECT in 10 treatment-naïve patients with SAD. In the first session, subjects were given an oral dose of CBD (400&#8201;mg) or placebo, in a double-blind procedure. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping. Relative to placebo, CBD was associated with significantly decreased subjective anxiety (p&#8201;<&#8201;0.001), reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus (p&#8201;<&#8201;0.001, uncorrected), and increased ECD uptake in the right posterior cingulate gyrus (p&#8201;<&#8201;0.001, uncorrected). These results suggest that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas.

Route(s)Oral
Dose(s)400 mg
Duration (days)
Participants10 patients with generalized social anxiety disorder
DesignControlled study
Type of publicationMedical journal
Address of author(s)Department of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. jcrippa@fmrp.usp.br
Full text

[Back to Overview]  [IACM Homepage]


up